A Phase 2 study of perifosine in advanced or metastatic breast cancer - PubMed (original) (raw)
Clinical Trial
A Phase 2 study of perifosine in advanced or metastatic breast cancer
Natasha B Leighl et al. Breast Cancer Res Treat. 2008 Mar.
Abstract
Background: First- and second-line chemotherapy with anthracyclines and taxanes in metastatic breast cancer yield a modest improvement in survival with potentially significant toxicity. Subsequent lines of chemotherapy yield response rates of 20-25%, with an unknown impact on survival. Perifosine, an oral alkylphospholipid structurally related to miltefosine, has marked activity against breast cancer cell lines and xenograft models, with broad spectrum cellular effects.
Objectives: To determine the efficacy and toxicity of perifosine in patients with metastatic breast cancer patients after up to 2 lines of prior chemotherapy for advanced disease.
Methods: 18 patients were enrolled, and 17 treated, using a loading/maintenance dose schedule, (day 1, 300 mg, maintenance 150 mg days 2-21) every 28 days, until disease progression or unacceptable toxicity.
Results: Median age of patients was 54 (28-69), 16/17 were female, ECOG performance status was 0/1 in 16 patients. Fifteen received at least 1 prior chemotherapy regimen for metastatic disease (maximum 2). A median of 2 cycles (range 1-13) was administered per patient. Sixteen were evaluable for response: 2 had SD for 4 cycles, 1 SD for 13 cycles, 13 progressed by cycle 2. Grade 3/4 drug-related non-hematologic toxicities include: diarrhea (2), vomiting (2), nausea (2), fatigue (2) and anorexia (1). No grade 3/4 hematologic toxicities were seen. Median time to progression was 8 weeks (7-15 weeks).
Conclusion: No objective responses were seen in this group of pretreated metastatic breast cancer patients. Disease stabilization was observed in 19% at 2 months.
Similar articles
- A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer.
Wolff AC, Armstrong DK, Fetting JH, Carducci MK, Riley CD, Bender JF, Casero RA Jr, Davidson NE. Wolff AC, et al. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5922-8. Clin Cancer Res. 2003. PMID: 14676116 Clinical Trial. - Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
Bailey HH, Mahoney MR, Ettinger DS, Maples WJ, Fracasso PM, Traynor AM, Erlichman C, Okuno SH. Bailey HH, et al. Cancer. 2006 Nov 15;107(10):2462-7. doi: 10.1002/cncr.22308. Cancer. 2006. PMID: 17058289 Clinical Trial. - Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Jung JY, Kwon JH, Kim JH, Song HH, Kim I, Lee KS, Kim HJ, Zang DY, Ahn JS, Lee JA, Park YI. Jung JY, et al. Oncol Rep. 2009 Feb;21(2):523-9. Oncol Rep. 2009. PMID: 19148531 Clinical Trial. - Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M. Steinberg M. Clin Ther. 2008 Sep;30(9):1590-617. doi: 10.1016/j.clinthera.2008.09.015. Clin Ther. 2008. PMID: 18840366 Review. - Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy.
Vink SR, van Blitterswijk WJ, Schellens JH, Verheij M. Vink SR, et al. Cancer Treat Rev. 2007 Apr;33(2):191-202. doi: 10.1016/j.ctrv.2006.12.001. Epub 2007 Feb 6. Cancer Treat Rev. 2007. PMID: 17287087 Review.
Cited by
- Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.
Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y, Lu B, Fan Y, Liu Z, Chen X, Jia X, Dong Z, Liu K. Liu F, et al. Mol Cancer. 2024 Jul 25;23(1):148. doi: 10.1186/s12943-024-02046-3. Mol Cancer. 2024. PMID: 39048965 Free PMC article. Review. - Mitochondrial Functionality Is Regulated by Alkylphospholipids in Human Colon Cancer Cells.
Torrens-Mas M, Collado-Solé A, Sola-Leyva A, Carrasco-Jiménez MP, Oliver J, Pons DG, Roca P, Sastre-Serra J. Torrens-Mas M, et al. Biology (Basel). 2023 Nov 22;12(12):1457. doi: 10.3390/biology12121457. Biology (Basel). 2023. PMID: 38132283 Free PMC article. - Targeting Protein Kinase C for Cancer Therapy.
He S, Li Q, Huang Q, Cheng J. He S, et al. Cancers (Basel). 2022 Feb 22;14(5):1104. doi: 10.3390/cancers14051104. Cancers (Basel). 2022. PMID: 35267413 Free PMC article. Review. - Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells.
Gong B, Zhang J, Hua Z, Liu Z, Thiele CJ, Li Z. Gong B, et al. Front Oncol. 2021 Jul 12;11:686898. doi: 10.3389/fonc.2021.686898. eCollection 2021. Front Oncol. 2021. PMID: 34322387 Free PMC article. - Perifosine and vitamin D combination induces apoptotic and non-apoptotic cell death in endometrial cancer cells.
Karagul MI, Aktas S, Yilmaz SN, Yetkin D, Celikcan HD, Cevik OS. Karagul MI, et al. EXCLI J. 2020 May 4;19:532-546. doi: 10.17179/excli2019-1834. eCollection 2020. EXCLI J. 2020. PMID: 32483402 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical